[{"id":"8fd31dd0-c717-4033-9f44-afbf209f365e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225039","created_at":"2021-03-09T19:53:36.498Z","updated_at":"2024-07-02T16:35:12.728Z","phase":"Phase 2","brief_title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","source_id_and_acronym":"NCT04225039","lead_sponsor":"University of Pennsylvania","biomarkers":" MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-26"},{"id":"099c10c0-ef78-481a-99a8-5823e77b325c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04470024","created_at":"2021-01-29T07:20:56.485Z","updated_at":"2024-07-02T16:35:41.337Z","phase":"Phase 1","brief_title":"Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC","source_id_and_acronym":"NCT04470024","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • DPV-001 • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/05/2021","start_date":" 08/05/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2023-08-01"},{"id":"cde40545-3e1d-4348-8d5c-12a3680adbe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126110","created_at":"2021-01-18T15:24:10.227Z","updated_at":"2024-07-02T16:35:58.465Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies","source_id_and_acronym":"NCT03126110","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ragifilimab (INCAGN1876)"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 11/09/2021","primary_completion_date":" 11/09/2021","study_txt":" Completion: 11/09/2021","study_completion_date":" 11/09/2021","last_update_posted":"2022-12-28"}]